Model for estimating the healthcare costs and capacity of intensive care units in Italy in the treatment of patients with COVID-19: remdesivir impact assessment

AboutOpen

View Publication Info
 
 
Field Value
 
Title Model for estimating the healthcare costs and capacity of intensive care units in Italy in the treatment of patients with COVID-19: remdesivir impact assessment
 
Creator Ruggeri, Matteo
Signorini, Alessandro
Drago, Carlo
Rosiello, Francesco
Marchetti, Marco
 
Description Introduction: Coronavirus disease 2019 (COVID-19) is caused by a severe acute respiratory syndrome coronavirus 2, which is a human coronavirus responsible for a pandemic. Direct interventions, i.e. physical distancing and use of protective devices, can prevent or limit contagions, however, it is also required to evaluate the optimization of limited resources, such as the Intensive Care Unit (ICU). For this purpose, it is relevant to estimate the impact of therapeutic solutions that reduce the probability that the patient transits to ICU in symptomatic subjects and in need of hospitalization. The therapeutic solutions allow a more rapid recovery of the patient and save scarce resources that can be used in the treatment of other patients.
Methods: A forecasting model is designed to estimate the impact of one therapeutic solution, i.e. the antiretroviral Remdesivir, on both the capacity of intensive care and the healthcare costs for hospitals when managing the current emergency. A base case is presented as well as a best and a worst case scenario deriving from the sensitivity analyses.
Results: The introduction of Remdesivir in patients receiving low-flow oxygen therapy with the purpose of reducing ICU accesses and deaths leads to 431 million euros cost savings and avoids 17,150 hospitalizations in intensive care and 6,923 deaths. In the best case, 294 million euros savings are estimated, whilst in the worst case the model estimates a saving of 512 million euros.
Conclusions: Remdesivir has the potential to reduce the negative effects of the Coronavirus disease, improving patient conditions and reducing death tolls, and can also save scarce healthcare resources during this pandemic, resulting in a shorter hospital stay and fewer ICU admissions. (Market Access)
 
Publisher AboutScience srl - Piazza Duca d'Aosta 12 - 20124 Milano MI (Italy)
 
Date 2020-12-17
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Original Research Article
 
Format application/pdf
application/epub+zip
text/html
application/pdf
application/epub+zip
text/html
 
Identifier https://journals.aboutscience.eu/index.php/aboutopen/article/view/2213
10.33393/abtpn.2020.2213
 
Source AboutOpen; Vol 7 No 1 (2020): January - December 2020; 95-102
AboutOpen; V. 7 N. 1 (2020): January - December 2020; 95-102
2465-2628
 
Language eng
 
Relation https://journals.aboutscience.eu/index.php/aboutopen/article/view/2213/2222
https://journals.aboutscience.eu/index.php/aboutopen/article/view/2213/2223
https://journals.aboutscience.eu/index.php/aboutopen/article/view/2213/2224
https://journals.aboutscience.eu/index.php/aboutopen/article/view/2213/2278
https://journals.aboutscience.eu/index.php/aboutopen/article/view/2213/2279
https://journals.aboutscience.eu/index.php/aboutopen/article/view/2213/2280
 
Rights Copyright (c) 2020 The Authors
http://creativecommons.org/licenses/by-nc/4.0
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library